You are here: Industry Insights > Zai Lab

News List

Zai Lab: How To Go Further after Cancelling B? Zhaoxiaoxia/PharmaSources
July 03, 2023
On November 11, 2022, Zai Lab announced that its HKEX stock code suffix -B is cancelled officially, which is another "Cancel B" company in Hong Kong stock market 18A after Baekje, Innovent, TopAlliance, Henlius and CanSino Biologics.
Qiming's Portfolio Company Zai Lab Lists on Main Board of HKEX prnasia
September 28, 2020
Qiming's portfolio company Zai Lab, an innovative commercial-stage biopharmaceutical company, officially listed on the Main Board of The Stock Exchange of Hong Kong, S.A.R., China Limited today.
Turning Point Therapeutics and Zai Lab Announce Exclusive License Agreement for Repotrectinib in Greater China prnasia
July 08, 2020
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, and Zai Lab (NASDAQ: ZLAB), an innovative commercial-stage biopharmaceutical company, today announced
Regeneron, Zai Lab Enter Strategic REGN1979 Alliance contractpharma
April 09, 2020
Regeneron will receive $30 million upfront and is eligible to receive up to $160 million in additional regulatory and sales milestones.
Sales of Zai Lab’s PARP Inhibitor Reaching RMB46.90 Million in Macau, S.A.R., China and Hong Kong, S.A.R., China of China in 2019 PharmaSources/Caicai
March 31, 2020
According to the 2019 results and company progress released by Zai Lab on Mar. 19, the total sales revenue of niraparib (trade name: Zejula) reached USD6.60 million (around RMB46.90 million) in Hong Kong, S.A.R., China and Macau, S.A.R., China Region of C
Zai Lab Announces NMPA Approval of ZEJULA in China americanpharmaceuticalreview
January 02, 2020
Zai Lab announced the China National Medical Products Administration (NMPA) approved the New Drug Application (NDA) for ZEJULA (niraparib) ...
Incyte and Zai Lab enter into $77.5M collaboration biospectrumasia
July 08, 2019
Incyte will retain an option to assist in the promotion of INCMGA0012 in Zai Lab’s licensed territories
Deciphera licenses cancer drug ripretinib to Zai Lab in China pharmaceutical-technology
June 13, 2019
US-based Deciphera Pharmaceuticals has signed an exclusive licence agreement with biopharmaceutical company Zai Lab to develop and commercialise cancer therapeutic ripretinib in Greater China.
Zai Lab cans ex-GlaxoSmithKline eczema drug after phase 2 flop fiercebiotech
August 27, 2018
Zai Lab has stopped development of a treatment for atopic dermatitis after it failed to beat placebo in a phase 2a trial.
Zai Lab appoints AstraZeneca's William Liang as CCO biospectrumasia
June 13, 2018
Prior to joining Zai Lab, William served as Vice President at AstraZeneca heading up the Oncology Business Unit in China

Previous page 1 2 Next page